Key Highlights

• Medibank Private Limited (ASX:MPL) reported its results for the year ended 30 June 2026 on 20 August 2026.

• Group Revenue rose 5.9% to A$9,115.2 million, group operating profit rose 6.7% to A$813.5 million, and underlying net profit after tax (NPAT) rose 2.9% to A$636.8 million.

• Statutory NPAT attributable to shareholders was A$638.7 million, up 27.5%.

• That jump largely reflects the prior year, which included a A$182.8 million pre-tax COVID-19 reserve movement, so the underlying figure is the cleaner guide to trading.

What does Medibank (ASX:MPL)'s latest result reveal about a Business that has to balance steady Health Insurance Earnings against a growing care operation? In short, it shows a company holding its insurance Margin while leaning harder on Medibank Health, with a Shareholder meeting on 18 November 2026 the next scheduled checkpoint.

The central development: FY26 results and the AGM ahead

Medibank Private Limited (ASX:MPL) reported its results for the year ended 30 June 2026 on 20 August 2026. Group revenue rose 5.9% to A$9,115.2 million, group operating profit rose 6.7% to A$813.5 million, and underlying net profit after tax (NPAT) rose 2.9% to A$636.8 million.

Statutory NPAT attributable to shareholders was A$638.7 million, up 27.5%. That jump largely reflects the prior year, which included a A$182.8 million pre-tax COVID-19 reserve movement, so the underlying figure is the cleaner guide to trading.

The Annual General Meeting is scheduled for 10.00am on 18 November 2026 in Melbourne, with virtual attendance available. Dr Amandeep Hansra is standing for election as a non-executive director, and the board recommends her election.

What Medibank does and how it earns money

Medibank is one of Australia's largest private health insurers, operating the Medibank and ahm brands. Most of its income comes from resident health insurance premiums, which totalled A$8,267.9 million in FY26, up 4.5%.

It also insures overseas students and visitors under a non-resident category, and runs Medibank Health, which provides care services such as home hospital programs and medical centres.

The key revenue drivers are therefore premium growth, the number of policyholders, and how much of each premium dollar is paid out in claims. The gap between the two is the gross margin.

Operating performance

Health insurance operating profit rose 3.8% to A$769.8 million, with the Operating Margin steady at 9.0%. Resident gross margin was 16.3%, up 10 basis points, while net resident claims expense rose 4.4% to A$6,918.2 million.

Net resident policyholders grew by 22,100, or 1.1%. The ahm Brand added 13,500 and Medibank added 8,600. Non-resident policy units fell 2.3% to 346,200, which the company linked to tighter migration settings, and non-resident gross margin eased by 210 basis points to 34.8%.

Operating expenses rose 7.1% to A$690.2 million, although the expense ratio held at 8.0% and management cited about A$10 million of productivity savings.

Net Investment income fell 13.9% to A$178.9 million, which tempered growth in the underlying result.

Total claims paid were about A$6.9 billion. The company says it delivered roughly A$299 million of customer value on top of that, including about A$250.5 million through its Members' Choice and no-gap networks and A$48.6 million in Live Better rewards. Those are company-calculated figures, not audited measures.

Cost discipline matters because expenses grew faster than premium revenue this year. Medibank says cumulative productivity savings since 2017 total A$132.4 million, and the group's effective tax rate for FY26 was 30.3%.

Medibank Health is the growth segment

Medibank Health revenue rose 30.8% to A$634.8 million, and segment profit rose 31.3% to A$100.7 million. The result includes twelve months of Amplar Health's home hospital operation and six months of Better Medical, for which A$163.5 million of Capital was deployed.

Gross margin in the segment fell 180 basis points to 51.5%, a reminder that acquired, service-heavy revenue tends to carry a different margin profile from insurance. For FY27, management expects segment profit growth of about 25%, including a full year of Better Medical. That is company guidance rather than a reported result.

Dividends and capital

The final fully franked Dividend was 10.9 cents per share, taking the FY26 ordinary dividend to 19.2 cents, up from 18.0 cents. The Payout Ratio was 83.0% of underlying NPAT on a normalised basis, within the 75% to 85% target range. The final dividend was paid on 8 October 2026.

APRA imposed a temporary A$250 million supervisory capital adjustment following the 2022 cybercrime event. Medibank held additional capital to offset it, lifting the Health Insurance required capital ratio to 13.3%, above the company's 10% to 12% target range. The fund's regulatory capital coverage was 1.9 times.

Sector conditions and competitive position

Private health insurance in Australia is shaped by regulated premium increases, ageing demographics and rising hospital costs. Insurers cannot freely reprice, so claims Inflation and the annual premium approval cycle matter greatly. Resident claims growth per policy unit was 2.6% in FY26, up 40 basis points.

Medibank competes with other large insurers and member-owned funds, and the dual-brand structure lets it address both premium and value-focused customers. Its Acquisition rate was 11.6% across the group, with ahm at 17.3% and Medibank at 9.9%, while the lapse rate was 10.5%. Those figures suggest ahm is the more encouraging acquisition engine, whereas the Medibank brand has been working to improve Volume momentum.

Risks and uncertainties

The cybercrime event of 2022 continues to carry costs. Non-recurring cyber costs were A$34.9 million in FY26, and the company expects them to be below A$20 million in FY27. That estimate excludes the effect of any findings or outcomes from regulatory investigations and litigation, which remain uncertain.

Other risks include the outcome of the 1 April 2027 premium round, claims inflation, further softness in non-resident numbers, and execution risk as acquisitions are integrated. Management has also said it has appetite and financial capacity for further acquisitions, which would add both opportunity and integration risk.

Investment returns are another swing factor, as the FY26 decline in net investment income showed.

What to watch next

Beyond the 18 November AGM, the main items are the FY27 outlook for resident gross margin, which the company expects to be broadly consistent with FY26 and subject to the April 2027 premium increase, and progress on regulatory matters tied to the cyber event.

Readers may also want to follow whether Medibank Health's guided profit growth is delivered, since that segment is where management is directing much of its acquisition spending, and whether the insurance margin holds as claims inflation evolves.